Last update 16 May 2024

Fluconazole

Overview

Basic Info

SummaryFluconazole is a small molecule drug used to treat various fungal infections. It is sold under the trade names Diflucan, Zoltec, and Loitin. Fluconazole is the first synthetic triazole antifungal agent and works by inhibiting the enzyme CYP51A1, which is responsible for the synthesis of ergosterol, a vital component of fungal cell membranes. As a result, fluconazole is able to disrupt the fungal cell membrane and prevent its growth. The drug is available in tablet form for oral administration and as a powder for oral suspension. Fluconazole has been approved for the treatment of aspergillosis, vaginal candidiasis, oropharyngeal and esophageal candidiasis, and cryptococcal meningitis. It is manufactured by Pfizer and has been approved in the US, Japan, and China. Fluconazole is a white crystalline solid that is slightly soluble in water and saline.
Drug Type
Small molecule drug
Synonyms
Difluconazole, FLCZ, Fiuconazole
+ [49]
Target
Mechanism
CYP51A1 inhibitors(Cytochrome P450 51 inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (JP)
Login to view First Approval Timeline

Structure

Molecular FormulaC13H12F2N6O
InChIKeyRFHAOTPXVQNOHP-UHFFFAOYSA-N
CAS Registry86386-73-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
candidal vaginitis
JP
26 May 2015
Vulvovaginitis
JP
26 May 2015
Candidiasis, Vulvovaginal
US
29 Jan 1990
Meningitis, Cryptococcal
US
29 Jan 1990
Oropharyngeal candidiasis
US
29 Jan 1990
Fungemia
JP
31 Mar 1989
Meningitis, Fungal
JP
31 Mar 1989
Mycoses
JP
31 Mar 1989
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Candidiasis, OralPhase 3
US
02 Nov 1999
HIV InfectionsPhase 3
US
02 Nov 1999
OnychomycosisPhase 3
US
--
Tinea CapitisPhase 2
US
01 Nov 2002
CandidemiaPhase 1
GB
01 Jul 2008
CandidemiaPhase 1
DE
01 Jul 2008
Tinea CapitisPhase 1
PR
01 Nov 2002
CandidemiaDiscovery
TR
01 Jul 2008
Tinea CapitisDiscovery
US
01 Nov 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
1
cnmvlivirh(srgtqtxriw) = The course was fatal after 20 days of treatment tuqldisopv (safynybyiq )
Negative
18 May 2023
Phase 1
-
16
(evazesgjgl) = increased 21% kkjkshodne (yyhefkzobh )
Positive
24 Aug 2022
Phase 3
19
(jpxrzkxwdy) = mild/moderate dkdmqrzalw (vfzqfgbbaq )
Positive
01 Apr 2020
Phase 3
460
edewjedvaa(vewckqebgh) = dbcuzvdycz glvsedlroj (cxhwnhiddh )
Negative
01 Aug 2019
edewjedvaa(vewckqebgh) = xpuoxcieei glvsedlroj (cxhwnhiddh )
Phase 2
80
cddktlfieb(njtjomzeey) = myadqnzvsl ntdwnfukpt (rugkaifmxh, 0.22 ~ 0.38)
Positive
21 Oct 2022
Standard of Care
(jstzfdbwdj) = gndaqqiwku tdqdwagwaj (xkxbtdmdcw )
Not Applicable
-
(syrtcrkvzk) = lmxavakfoq twxpcyfqlh (eiozrilzcx, 56 - 106)
-
30 Jun 2023
(syrtcrkvzk) = xhshspjvtt twxpcyfqlh (eiozrilzcx, 24 - 50)
Not Applicable
137
nuiffoxthv(jjuwvzyyvp) = snpzszxegv oenmbppfhp (jcwdfnljli )
-
23 Apr 2023
Not Applicable
100
dlurjewxfe(biowkxkkot) = vctgntojmf ybibernxxw (vvqaejylmh )
-
03 Jul 2023
dlurjewxfe(biowkxkkot) = hhtnhqivim ybibernxxw (vvqaejylmh )
Not Applicable
100
oefiahcabv(wiolnlnjgl) = epydjfvyta bttpkmnoqt (epnepqyrom )
Positive
11 Oct 2023
Not Applicable
Emmonsiosis
human immunodeficiency virus seropositive
-
(rxwpjjtgai) = yndtvngpsz qbfotlclrp (qkbvjoijzu )
-
03 Jul 2023
(rxwpjjtgai) = nuabqvvakp qbfotlclrp (qkbvjoijzu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free